Revenue increased driven by recovery in domestic life science research support services, while overseas remained weak. Overall net sales were 253 million yen, operating loss was -4 million yen, ordinary loss was -0 million yen, and net income attributable to owners of parent was -3 million yen. Q1 was driven by increased domestic projects.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6090","jir_company_name":"Human Metabolome Technologies, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/6090-20261111-01.pdf","jir_short_summary":"Revenue increased driven by recovery in domestic life science research support services, while overseas remained weak. Overall net sales were 253 million yen, operating loss was -4 million yen, ordinary loss was -0 million yen, and net income attributable to owners of parent was -3 million yen. Q1 was driven by increased domestic projects.","jir_summary":"### Earnings Overview\nNet sales for this quarter amounted to 253 million yen (significant increase year over year), driven by an increase in large domestic life science research support service contracts. Functional materials development support services (FDS) and bio-manufacturing support services (BMS) decreased due to a seasonal trough, but overall gross profit improved, narrowing operating and ordinary losses. Overseas performance remained weak.\n\n### Outlook and Considerations\nContinued acquisition of large domestic contracts is important. Balancing recovery in overseas sales with cost management will be key. Note that the supplementary earnings materials may be subject to variability depending on macro trends and progress in R&D.","jir_financial_highlights":"Net Sales: 253 (YoY change: increase of 61 compared to Q1 FY2026)\nOperating Income: - 4 (Change: -4)\nOrdinary Income: 0 (Change: 0)\nNet Income Attributable to Owners of Parent: - 3 (Change: -3)\nNet Income per Share: - 0.59 (Change: -0.59)","jir_category":"","jir_hashtags":"#HumanMetabolome, #EarningsInfo","jir_key_figures":"Net Sales: 253 million yen\nOperating Income: -4 million yen\nNet Income Attributable to Owners of Parent: -3 million yen","jir_meta_title":"Human Metabolome Technologies, Inc. Q1 FY2027 Supplementary Earnings Materials | Domestic Recovery, Overseas Weakness","jir_meta_description":"Supplementary materials for Q1 FY2027 of Human Metabolome Technologies, Inc. Net sales: 253 million yen; operating loss: -4 million yen. Summary of key indicators and segment trends, including weak overseas markets and contributions from large domestic projects.","jir_og_title":"Human Metabolome Technologies, Inc. Q1 FY2027 Supplementary Earnings Materials","jir_og_description":"Recovery in domestic life science support drove higher sales while overseas remained weak. Explanation of primary drivers for this quarter and key considerations going forward.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":60381,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149234","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n